Author

R. Belizaire

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Vedder· 1 shared B. J. E. Martin· 1 shared B. L. Ebert· 1 shared C. Hartigan· 1 shared C. Stanclift· 1 shared E. C. Wheeler· 1 shared E. Padron· 1 shared J. C. Jann· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Vedder

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivSep 26, 2022

Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS/AML

E. C. Wheeler, B. J. E. Martin, W. C. Doyle…·Z. Tothova

The paper shows SF3B1 splicing modulators impair DNA damage response in cohesin-mutant MDS/AML, leading to increased sensitivity to PARP inhibitors and chemotherapy.

DOI 10.1126/scitranslmed.ade2774

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintApr 13, 2020

CBL mutations promote activation of PI3K/AKT signaling via LYN kinase

R. Belizaire, S. H. J. Koochaki, N. Udeshi…·B. L. Ebert

The paper investigates how CBL mutations drive oncogenesis by enhancing LYN kinase activity and PI3K/AKT signaling, suggesting LYN inhibition as a therapeutic strategy.

DOI 10.1101/2020.04.13.038448

humanproteomics

𝕏 PostBluesky